CKMT2-AS1: A Potential Drug Target and Biomarker (G100131067)

Target Name: CKMT2-AS1

NCBI ID: G100131067

CKMT2-AS1

Other Name(s): CKMT2 antisense RNA 1, transcript variant 1 | CKMT2 antisense RNA 1

CKMT2-AS1: A Potential Drug Target and Biomarker

Cystic fibrosis (CF) is a chronic genetic disease that affects the respiratory and digestive systems. It is characterized by the production of thick, sticky mucus that clogs the airways and causes chronic coughing, wheezing, and digestive problems. According to the World Health Organization (WHO), there are over 700,000 people worldwide with CF, and it is the third leading cause of chronic illness in the United States.

One of the main causes of CF is the mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The CFTR gene is a protein that is located on the genetic makeup of the CFTR gene, which is responsible for producing the CFTR protein. The CFTR protein plays a crucial role in the regulation of salt and water transport in and out of cells, which is essential for many different bodily functions, including maintaining the proper balance of fluids and electrolytes in the body.

CKMT2-AS1 is a gene that has been identified as a potential drug target for CF. The CKMT2-AS1 gene is located on the genetic makeup of individuals with CF and has been shown to be involved in the regulation of CFTR protein. Specifically, studies have shown that individuals with CF have reduced levels of the CKMT2-AS1 gene compared to healthy individuals.

In addition to its potential as a drug target, CKMT2-AS1 has also been identified as a potential biomarker for CF. The CKMT2-AS1 gene has been shown to be expressed in the lungs and other organs of individuals with CF, and it has been used as a biomarker to diagnose and track the severity of CF.

One of the main advantages of CKMT2-AS1 as a drug target is its location on the genetic makeup of CFTR. This means that any changes in the CKMT2-AS1 gene could potentially be linked to changes in the CFTR protein. Additionally, CKMT2-AS1 has been shown to be involved in the regulation of CFTR protein, which is the primary protein involved in the development and progression of CF.

Another potential advantage of CKMT2-AS1 as a drug target is its role in the regulation of salt and water transport. This is important for many different bodily functions, including maintaining the proper balance of fluids and electrolytes in the body. Additionally, CKMT2-AS1 has been shown to be involved in the regulation of cell signaling pathways, which could potentially make it a useful target for drugs that target signaling pathways involved in many different diseases.

In conclusion, CKMT2-AS1 is a gene that has been identified as a potential drug target and biomarker for CF. Its location on the genetic makeup of CFTR and its involvement in the regulation of salt and water transport make it a promising target for drugs that target CFTR signaling pathways. Further research is needed to determine the effectiveness of CKMT2-AS1 as a drug and to develop biomarkers for CF.

Protein Name: CKMT2 Antisense RNA 1

The "CKMT2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CKMT2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets